fixed swr [RSABE / ABEL]

posted by martin  – Austria, 2013-03-29 16:07 (4840 d 14:58 ago) – Posting: # 10311
Views: 31,207

Hi Helmut !

Yep; your are totally right (should have done my homework first ;-)). what about defining the extent of scaling after interim analysis of the first stage data (CV estimated in 1st stage) within a group-sequential adaptive design?

Drawback: BUT what if the CV at interim is smaller than 0.3 ... :confused:

best regards

martin

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
314 visitors (0 registered, 314 guests [including 23 identified bots]).
Forum time: 08:05 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5